Specimens

标本核心支持UCSD SPOTRIAS网站和SPOTRIAS国家网络的所有活动， 通过安排从急性卒中、TIA患者中采集、储存和运输标本， 模拟条件。具体目标1继续我们的常规程序，以获得，处理和储存血液 急性患者在多个时间点的样本。我们已经建立了抽血协议， 急诊科、重症监护病房和普通病房。一些 程序确保所有SPOTRIAS标本的质量处理和标记。具体目标2建议， 推导出一组血清标志物，旨在帮助预测短暂性缺血后未来的缺血事件。 TIA发作。重要的是尝试将TIA患者分为高风险组和低风险组， ABCD2模型或血清生物标志物已被前瞻性验证用于此目的。我们将得到一个 多标志物面板，显示出对估计随后卒中风险的良好预测价值，然后 将衍生生物标志物组的预测值与ABCD 2方法进行比较。同意后，血液 在TIA患者入院后，将尽快抽取样本。血液将被运送到Biosite， 股份有限公司、用于测定。主要终点为TIA后90天新发卒中的发生率。二次 终点为90天NIHSS和改良兰金量表。我们还将计算ABCD2预测 对于每一个病人。我们希望临床评估ABCD2能够合理预测随后的卒中风险， 预测值我们希望能够得到一个多标记的生物标志物小组， ROC曲线的合理AUC。我们将确定这两种方法是否上级另一种。

The specimen core supports all activities of the UCSD SPOTRIAS site, and the SPOTRIAS national network, by arranging for the collection, storage, and shipment of specimens from patients with acute stroke, TIA, and mimic conditions. Specific Aim 1 continues our routine procedures to obtain, process, and store blood specimens from acute patients at multiple time points. We have established blood-drawing protocols in the emergency departments, intensive care units, and general wards at our collaborating sites. A number of procedures ensure quality handling and labeling of all SPOTRIAS specimens. Specific Aim 2 proposes to derive a panel of serum markers designed to help predict future ischemic events after transient ischemic attack (TIA). It is important to attempt to stratify TIA patients into high- and low-risk groups, and neither the ABCD2 model nor serum biomarkers has been prospectivelv validated for this purpose. We will derive a multi-marker panel that shows good predictive value for estimating subsequent stroke risk, and then compare the predictive value of the derived biomarker panel to the ABCD2 method. After consent, blood samples will be drawn as soon as practical after admission of TIA patients. Blood will be shipped to Biosite, Inc., for assay. The primary endpoint will be the 90-day incidence of new stroke after TIA. Secondary endpoints will be the 90-day NIHSS and modified Rankin Scale. We will also compute an ABCD2 prediction for each patient. We expect the clinical estimate, ABCD2, to predict subsequent stroke risk with reasonable predictive value. We expect to be able to derive a multi-marker panel of biomarkers that also has a reasonable AUC for the ROC curve. We will determine whether either method is superior to the other.